Lung Drug Delivery via Segmented Microbubble-Nanoparticle System

The patent segments the drug delivery system into two distinct components: microparticles (1-100 µm) that passively target lung capillaries through size-based mechanical retention, and nanoparticles (10-500 nm) that actively target tumor cells via surface ligands. This segmentation allows the system to achieve both high local drug concentration in the lung and selective tumor cell uptake, thereby improving efficacy while reducing systemic toxicity to healthy tissues

The patent implements local quality by equipping nanoparticles with specific surface ligands (such as antibodies, peptides, or small molecules) that recognize and bind to receptors overexpressed on tumor cell surfaces. This localized molecular recognition ensures that the cytotoxic payload is delivered preferentially to malignant cells within the lung, maximizing therapeutic effect while minimizing damage to surrounding healthy lung tissue and other organs

The dual-component architecture separates the targeting function (microparticles) from the therapeutic function (nanoparticles with cytotoxic payload). This segmentation enables the system to achieve high local drug concentrations at the tumor site through passive pulmonary retention and active cellular targeting, thereby improving treatment reliability without requiring high systemic dosages that would cause severe side effects

The microparticles act as intermediaries that first accumulate in lung capillaries through passive targeting, creating a localized reservoir that subsequently releases nanoparticles for tumor cell uptake. This two-stage intermediary mechanism ensures efficient drug delivery to the target while maintaining low systemic drug levels, thus improving efficacy without proportionally increasing toxicity

The patent applies local quality by conjugating specific ligands only to the surface of nanoparticles intended for tumor targeting, while keeping the core structure and microparticle component relatively simple. This localized functionalization achieves high targeting specificity without requiring complex modifications throughout the entire delivery system, thereby balancing precision with manufacturability

The patent employs composite materials by combining nanoparticle cores (made from biocompatible polymers, lipids, or inorganic materials) with surface-bound ligands (antibodies, peptides, or small molecules). This composite structure integrates the simplicity of conventional nanoparticle synthesis with the specificity of bioactive ligands, achieving high targeting precision while maintaining relative ease of manufacture through established conjugation chemistries